BioCatalystWatch
GYREWorkspace / GYRE / OverviewCompany library
GYRE THERAPEUTICS, INC. logo

GYRE THERAPEUTICS, INC.

GYRE THERAPEUTICS, INC. (GYRE)

Website

Price
Market cap
Next catalystExpected 1H 2027CG001419 — planned China Phase 2 cancer-pain study · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

F351 (hydronidone)

Small molecule

p38γ kinase × TGF-β1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

F351 (hydronidone)

Small molecule

p38γ kinase × TGF-β1

Upcoming / outlook

F528

Upcoming / outlook

F573

Caspase-1 × Caspase-3 × Caspase-6 × Caspase-7 × Caspase-8 × Caspase-9

PreINDP1P2P3FilingApproved
Upcoming / outlook

CG001419

TRKA × TRKB × TRKC

PreINDP1P3FilingApproved
Upcoming / outlook

CG620953

TYK2 × JAK1

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CG923308

CDK2 × Cyclin E

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

F528

Upcoming / outlook

F573

Caspase-1 × Caspase-3 × Caspase-6 × Caspase-7 × Caspase-8 × Caspase-9

PreINDP1P2P3FilingApproved
Upcoming / outlook

CG923308

CDK2 × Cyclin E

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CG001419

TRKA × TRKB × TRKC

PreINDP1P3FilingApproved
Upcoming / outlook

F351 (hydronidone)

Small molecule

p38γ kinase × TGF-β1

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

F351 (hydronidone)

Small molecule

p38γ kinase × TGF-β1

PreINDP1P2P3FilingApproved
CG009301

GSPT1

PreINDP1P2P3FilingApproved
Upcoming / outlook

CG009301

GSPT1

F230

Small molecule

Endothelin receptor A (ETA)

PreINDP1P2P3FilingApproved
F573

Caspase-1 × Caspase-3 × Caspase-6 × Caspase-7 × Caspase-8 × Caspase-9

PreINDP1P2P3FilingApproved
Upcoming / outlook

CG001419

TRKA × TRKB × TRKC

PreINDP1P2P3FilingApproved
CB 4332

PreINDP1P2P3FilingApproved
Systemic complement

C4b

PreINDP1P2P3FilingApproved

Partner / License out

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

C3

Approved / commercial

Thrombopoietin receptor

Approved

PreINDP1P2P3FilingApproved

Thrombopoietin receptor

Approved

PreINDP1P2P3FilingApproved

History / paused

CG001419

TRKA × TRKB × TRKC

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

GYRE PR & News

PR & News

GYRE SEC archive